These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 37526849)

  • 41. The Regulatory Evaluation of Vaccines for Human Use.
    Baylor NW
    Methods Mol Biol; 2016; 1404():773-787. PubMed ID: 27076337
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Regulatory oversight of cell therapy in China: Government's efforts in patient access and therapeutic innovation.
    Wu W; Wang Y; Tang Z; Gao Y; Huo Y
    Pharmacol Res; 2020 Aug; 158():104889. PubMed ID: 32428666
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States.
    Iglesias-Lopez C; Obach M; Vallano A; Agustí A
    Cytotherapy; 2021 Mar; 23(3):261-274. PubMed ID: 33483292
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Current regulatory issues in cell and tissue therapy.
    Burger SR
    Cytotherapy; 2003; 5(4):289-98. PubMed ID: 12944234
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical Trials on Advanced Therapy Investigational Medicinal Products in Spain (2004-2022): Experience and Challenges for the Future.
    Estévez Álamo J; Timón M; Sánchez Afán de Rivera I; Iriarte Torres B; Serrano Castro MA
    Adv Exp Med Biol; 2023; 1430():23-39. PubMed ID: 37526840
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Raising the standard: changes to the Australian Code of Good Manufacturing Practice (cGMP) for human blood and blood components, human tissues and human cellular therapy products.
    Wright C; Velickovic Z; Brown R; Larsen S; Macpherson JL; Gibson J; Rasko JE
    Pathology; 2014 Apr; 46(3):177-83. PubMed ID: 24614714
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Introduction to risk management plans in the Singapore context.
    Ho CSC; Tan LLB; Chan CL
    Singapore Med J; 2019 Sep; 60(9):483-486. PubMed ID: 31570951
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A roundtable on responsible innovation with autologous stem cells in Australia, Japan and Singapore.
    Lysaght T; Munsie M; Castricum A; Hui JHP; Okada K; Sato Y; Sawa Y; Stewart C; Tan LK; Tan LHY; Sugii S
    Cytotherapy; 2018 Sep; 20(9):1103-1109. PubMed ID: 30131270
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Regulatory requirements regarding cell-based medicinal products for human and veterinary use - a comparison].
    Kuhlmann-Gottke J; Duchow K
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Nov; 58(11-12):1299-305. PubMed ID: 26369765
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Regulation Policy on Cell- and Tissue-Based Therapy Products in Korea.
    Lim JO
    Tissue Eng Part A; 2015 Dec; 21(23-24):2791-6. PubMed ID: 25759938
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A few ethical issues in translational research for gene and cell therapy.
    Riva L; Petrini C
    J Transl Med; 2019 Nov; 17(1):395. PubMed ID: 31779636
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Regenerative medicine legislation in Japan for fast provision of cell therapy products.
    Fujita Y; Kawamoto A
    Clin Pharmacol Ther; 2016 Jan; 99(1):26-9. PubMed ID: 26482927
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Regulatory Pathway for Advanced Cell Therapy and Gene Therapy Products in Brazil: A Road to Be Built.
    de Freitas DR
    Adv Exp Med Biol; 2015; 871():213-9. PubMed ID: 26374221
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Update on Regulation of Regenerative Medicine in Taiwan.
    Chao WY; Chang YT; Tsai YT; Huang MC; Lin YC; Wu MM; Chi JF; Lin CL; Cheng HF; Wu SM
    Adv Exp Med Biol; 2023; 1430():211-219. PubMed ID: 37526850
    [TBL] [Abstract][Full Text] [Related]  

  • 55. International Society for Cell & Gene Therapy Position Paper: Key considerations to support evidence-based cell and gene therapies and oppose marketing of unproven products.
    Ikonomou L; Cuende N; Forte M; Grilley BJ; Levine AD; Munsie M; Rasko JEJ; Turner L; Bidkhori HR; Ciccocioppo R; Grignon F; Srivastava A; Weiss DJ; Zettler P; Levine BL;
    Cytotherapy; 2023 Sep; 25(9):920-929. PubMed ID: 37517865
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [International approaches to the regulation of cell therapy products].
    Piatigorskaia NV; Tulina MA; Aladysheva ZhI; Beregovykh VV
    Vestn Ross Akad Med Nauk; 2013; (8):4-8. PubMed ID: 24340637
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A decade of marketing approval of gene and cell-based therapies in the United States, European Union and Japan: An evaluation of regulatory decision-making.
    Coppens DGM; de Wilde S; Guchelaar HJ; De Bruin ML; Leufkens HGM; Meij P; Hoekman J
    Cytotherapy; 2018 Jun; 20(6):769-778. PubMed ID: 29730080
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Current Trends in Clinical Development of Gene and Cellular Therapeutic Products for Cancer in Japan.
    Nagai S; Sugiyama D
    Clin Ther; 2019 Jan; 41(1):174-184.e3. PubMed ID: 30528048
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Potency Assays: The 'Bugaboo' of Stem Cell Therapy.
    Torrents S; Grau-Vorster M; Vives J
    Adv Exp Med Biol; 2023; 1420():29-38. PubMed ID: 37258782
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cell and gene therapy products in Malaysia: a snapshot of the industry's current regulation preparedness.
    Loh EYX; Goh PS; Mannan AMM; Mohd Sani N; Ab Ghani A
    Cytotherapy; 2021 Dec; 23(12):1108-1113. PubMed ID: 34362651
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.